Miles
Executive Summary
Forms Biological Products unit and new Biotechnology Business unit headed by Ralph Galustian and George Scangos, PhD, respectively. Galustian will continue in his current role as president of the expanded Biological Products unit, which is part of the Miles Pharmaceutical Division based in West Haven, Conn., company announces Sept. 9. The unit will have global responsibility for manufacturing and creating international strategic marketing partnerships for plasma-derived products and biotechnologically derived products. The unit, which employs 1,700 people, has manufacturing sites in Clayton, N.C., Berkeley and Covina, Calif. and Spokane, Wash. and annual sales of about $500 mil. The new biotech business unit, with offices in Berkeley and West Haven, will bring together research institutes formerly spread throughout Miles and its German parent Bayer AG, and will be responsible for licensing R&D and production of all biotech products. The biotechnology unit employs 1,100 people. The reorganization becomes effective Oct. 1.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth